Loss of antiphospholipid antibody positivity post-thrombosis in SLE

被引:18
作者
Khawaja, Muznay [1 ]
Magder, Laurence [2 ]
Goldman, Daniel [3 ]
Petri, Michelle A. [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Med, Div Rheumatol, Baltimore, MD 21205 USA
[2] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA
[3] Johns Hopkins Univ, Rheumatol, Baltimore, MD USA
关键词
antibodies; antiphospholipid; anticardiolipin; lupus erythematosus; systemic; SYSTEMIC-LUPUS-ERYTHEMATOSUS; INTERNATIONAL CONSENSUS STATEMENT; US COHORT LUMINA; VIPER VENOM TIME; RISK-FACTORS; ANTICARDIOLIPIN ANTIBODIES; CLASSIFICATION CRITERIA; RECURRENT THROMBOSIS; ARTERIAL THROMBOSIS; CLINICAL-COURSE;
D O I
10.1136/lupus-2020-000423
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Purpose Loss of positivity of antiphospholipid antibodies has been observed in clinical practice post-thrombosis in patients with SLE with secondary antiphospholipid syndrome (APS). Our study defined the frequency of this loss and the duration before positivity recurred. Methods In this prospective study, patients with SLE having at least two positive antiphospholipid markers prior to thrombosis and at least 1 year of follow-up after thrombosis were included. Antiphospholipid markers included lupus anticoagulant (dilute Russell viper venom test >45 s followed by mixing and confirmatory tests) and/or anticardiolipin titre (aCL IgG >= 20, aCL IgM >= 20 and/or aCL IgA >= 20). The percentage of visits with positive antiphospholipid markers after thrombosis was calculated. For patients with a negative antiphospholipid marker any time after thrombosis, survival estimates were performed to calculate the time to return of antiphospholipid positivity. Results In APS due to SLE, complete loss of antiphospholipid positivity post-thrombosis was up to 41% for aCL IgG, 51% for IgM and 50% for IgA, but only 20% for those with lupus anticoagulant. Of those who at some point lost aCL IgG or became negative for lupus anticoagulant, the majority (60% and 76%, respectively) reacquired the antibody within 5 years. In contrast, of those who lost aCL IgM or IgA, fewer reacquired it within 5 years (37% and 17%, respectively). Conclusion Intermittent positivity of antiphospholipid antibodies is present in APS due to SLE. These fluctuations make it difficult to decide on length of anticoagulation. Lupus anticoagulant is more likely to persist post-thrombosis.
引用
收藏
页数:7
相关论文
共 60 条
[1]   Utility of Antiphosphatidylserine/Prothrombin and IgA Antiphospholipid Assays in Systemic Lupus Erythematosus [J].
Akhter, Ehtisham ;
Shums, Zakera ;
Norman, Gary L. ;
Binder, Walter ;
Fang, Hong ;
Petri, Michelle .
JOURNAL OF RHEUMATOLOGY, 2013, 40 (03) :282-286
[2]   ANTIPHOSPHOLIPID ANTIBODIES AND THE ANTIPHOSPHOLIPID SYNDROME IN SYSTEMIC LUPUS-ERYTHEMATOSUS - A PROSPECTIVE ANALYSIS OF 500 CONSECUTIVE PATIENTS [J].
ALARCONSEGOVIA, D ;
DELEZE, M ;
ORIA, CV ;
SANCHEZGUERRERO, J ;
GOMEZPACHECO, L ;
CABIEDES, J ;
FERNANDEZ, L ;
DELEON, SP .
MEDICINE, 1989, 68 (06) :353-365
[3]   Antiphospholipid Antibodies and Recurrent Thrombotic Events: Persistence and Portfolio [J].
Amory, Colum F. ;
Levine, Steven R. ;
Brey, Robin L. ;
Gebregziabher, Mulugeta ;
Tuhrim, Stanley ;
Tilley, Barbara C. ;
Simpson, Ann-Catherin C. ;
Sacco, Ralph L. ;
Mohr, Jay P. .
CEREBROVASCULAR DISEASES, 2015, 40 (5-6) :293-300
[4]   Estimated Frequency of Antiphospholipid Antibodies in Patients With Pregnancy Morbidity, Stroke, Myocardial Infarction, and Deep Vein Thrombosis: A Critical Review of the Literature [J].
Andreoli, Laura ;
Chighizola, Cecilia B. ;
Banzato, Alessandra ;
Pons-Estel, Guillermo J. ;
de Jesus, Guilherme Ramire ;
Erkan, Doruk .
ARTHRITIS CARE & RESEARCH, 2013, 65 (11) :1869-1873
[5]  
Bobba RS, 2007, J RHEUMATOL, V34, P1522
[6]   Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) -: XXV.: Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients [J].
Calvo-Alén, J ;
Toloza, SMA ;
Fernández, M ;
Bastian, HM ;
Fessler, BAJ ;
Roseman, JM ;
McGgwin, G ;
Vilád, LM ;
Reveille, JD ;
Alarcón, GS .
ARTHRITIS AND RHEUMATISM, 2005, 52 (07) :2060-2068
[7]   Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients [J].
Cervera, R. ;
Serrano, R. ;
Pons-Estel, G. J. ;
Ceberio-Hualde, L. ;
Shoenfeld, Y. ;
de Ramon, E. ;
Buonaiuto, V. ;
Jacobsen, S. ;
Zeher, M. M. ;
Tarr, T. ;
Tincani, A. ;
Taglietti, M. ;
Theodossiades, G. ;
Nomikou, E. ;
Galeazzi, M. ;
Bellisai, F. ;
Meroni, P. L. ;
Derksen, R. H. W. M. ;
de Groot, P. G. D. ;
Baleva, M. ;
Mosca, M. ;
Bombardieri, S. ;
Houssiau, F. ;
Gris, J-C ;
Quere, I. ;
Hachulla, E. ;
Vasconcelos, C. ;
Fernandez-Nebro, A. ;
Haro, M. ;
Amoura, Z. ;
Miyara, M. ;
Tektonidou, M. ;
Espinosa, G. ;
Bertolaccini, M. L. ;
Khamashta, M. A. .
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (06) :1011-1018
[8]   Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative [J].
Coloma Bazan, Emmanuel ;
Donate Lopez, Carolina ;
Moreno Lozano, Pedro ;
Cervera, Ricard ;
Espinosa, Gerard .
IMMUNOLOGIC RESEARCH, 2013, 56 (2-3) :358-361
[9]  
Comarmond C, 2017, LUPUS, V26, P1291, DOI 10.1177/0961203317699285
[10]   A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome [J].
Crowther, MA ;
Ginsberg, JS ;
Julian, J ;
Denburg, J ;
Hirsh, J ;
Douketis, J ;
Laskin, C ;
Fortin, P ;
Anderson, D ;
Kearon, C ;
Clarke, A ;
Geerts, W ;
Forgie, M ;
Green, D ;
Costantini, L ;
Yacura, W ;
Wilson, S ;
Gent, M ;
Kovacs, MJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (12) :1133-1138